BioSpace News Archive

Angiograms are common procedures used to diagnose many conditions, according to the SVS, and vascular surgeons use them to find out if you have a blockage in one of your arteries.

The Ultra-High Resolution CT System Delivers Twice the Resolution of Today’s CT Systems

Ionis earns $30 million license fee for IONIS-AZ6-2.5-L Rx

Merck announced that the pivotal Phase 3 KEYNOTE-042 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS).

Cellect Biotechnology Ltd. announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using Cellect’s FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products’ manufacturing.

NanoViricides, Inc. reports that its drug candidates in the HerpeCide™ program have been found to be safe based on multiple parameters in the recently completed initial non-GLP safety/toxicology study.

GNC Holdings, Inc. (NYSE: GNC) (the “Company”) will release results for the first quarter of 2018 before the market opens on April 26, 2018.

Adapt Pharma today welcomed the important steps recently taken by both the Ontario Government, and the Canadian Government to help address the opioid crisis, through free of charge access to NARCAN™ (naloxone hydrochloride) Nasal Spray.

Study meets its primary endpoint

Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.